4
Participants
Start Date
January 9, 2018
Primary Completion Date
April 17, 2019
Study Completion Date
January 11, 2021
Aldoxorubicin HCl
Aldoxorubicin hydrochloride
ETBX-011
Ad5 \[E1-, E2b-\]-CEA
ETBX-021
Ad5 \[E1-, E2b-\]-HER2
ETBX-051
Ad5 \[E1-, E2b-\]-Brachyury vaccine
ETBX-061
Ad5 \[E1-, E2b-\]-MUC1
GI-4000
Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
GI-6207
Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
GI-6301
Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
haNK for infusion
NK-92 \[CD16.158V, ER IL-2\]
Avelumab
Recombinant human anti-PD-L1 IgG1 monoclonal antibody
bevacizumab
Recombinant human anti-VEGF IgG1 monoclonal
Capecitabine
5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Cetuximab
Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
Cisplatin
cis-diamminedichloroplatinum(II)
Cyclophosphamide
2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Fluorouracil
5-fluoro-2,4 (1H,3H)-pyrimidinedione
Leucovorin
L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
nab-Paclitaxel
Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
Necitumumab
Necitumumab is a recombinant human lgG1 monoclonal antibody.
SBRT
Stereotactic Body Radiation Therapy
N-803
Recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RuSu/IgGI Fe complex1)
Chan Soon-Shiong Institute for Medicine, El Segundo
Lead Sponsor
ImmunityBio, Inc.
INDUSTRY